A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From ≥18 Years of Age to <50 Years of Age

NCT05995275 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

351

Enrollment

INDUSTRY

Sponsor class

Conditions

Smallpox
Mpox

Interventions

BIOLOGICAL: mRNA-1769
OTHER: Placebo

Sponsor

ModernaTX, Inc.